Showing results (191-200 of 207) with videos related to
Sort By:
Pageof 21
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.Blood|April 14, 2011
Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adultsItziar Salaverria, Claudia Philipp, Ilske Oschlies, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphomaUlrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.Blood|February 24, 2007
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Ute Berger, Markus Pfirrmann, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.Haematologica|September 24, 2016
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trialChristian Straka, Peter Liebisch, Hans Salwender, et al.Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemiaSanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.Pageof 21